Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s).,Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

当前位置： X-MOL 学术 › Biochim Biophys Acta Rev Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s).
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ( IF 9.7 ) Pub Date : 2019-10-30 , DOI: 10.1016/j.bbcan.2019.188318
Joseph Carmicheal ₁ , Asish Patel ₂ , Vipin Dalal ₁ , Pranita Atri ₁ , Amaninder S Dhaliwal ₃ , Uwe A Wittel ₄ , Mokenge P Malafa ₅ , Geoffrey Talmon ₆ , Benjamin J Swanson ₆ , Shailender Singh ₃ , Maneesh Jain ₇ , Sukhwinder Kaur ₁ , Surinder K Batra ₈

Affiliation

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA; Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA.
Department of Internal Medicine, Division of Gastroenterology-Hepatology, University of Nebraska Medical Center, Omaha, NE, USA.
Department of General- and Visceral Surgery, University of Freiburg Medical Center, Faculty of Medicine, Freiburg, Germany.
Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA; Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA; Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.

Pancreatic ductal adenocarcinoma (PDAC) is an incredibly deadly disease with a 5-year survival rate of 9%. The presence of pancreatic cystic lesions (PCLs) confers an increased likelihood of future pancreatic cancer in patients placing them in a high-risk category. Discerning concurrent malignancy and risk of future PCL progression to cancer must be carefully and accurately determined to improve survival outcomes and avoid unnecessary morbidity of pancreatic resection. Unfortunately, current image-based guidelines are inadequate to distinguish benign from malignant lesions. There continues to be a need for accurate molecular and imaging biomarker(s) capable of identifying malignant PCLs and predicting the malignant potential of PCLs to enable risk stratification and effective intervention management. This review provides an update on the current status of biomarkers from pancreatic cystic fluid, pancreatic juice, and seromic molecular analyses and discusses the potential of radiomics for differentiating PCLs harboring cancer from those that do not.

中文翻译：

胰腺囊性病变分层的升高：当前和未来的胰腺癌生物标志物。

胰腺导管腺癌（PDAC）是一种致命的疾病，其5年生存率为9％。胰腺囊性病变（PCL）的存在使高危人群中将来发生胰腺癌的可能性增加。必须仔细，准确地确定并发的恶性肿瘤和将来PCL演变为癌症的风险，以改善生存结果并避免不必要的胰腺切除术。不幸的是，当前基于图像的指南不足以区分良性和恶性病变。仍然需要能够鉴定恶性PCL并预测PCL的恶性潜力以实现风险分层和有效干预管理的准确的分子和成像生物标志物。

更新日期：2019-10-30

点击分享查看原文

点击收藏

阅读更多本刊最新论文